Add time:08/20/2019 Source:sciencedirect.com
Based on the original spirodiketopiperazine design framework, further optimization of an orally available CCR5 antagonist was undertaken. Structural hybridization of the hydroxylated analog 4 derived from one of the oxidative metabolites and the new orally available non-hydroxylated benzoic acid analog 5 resulted in another potent orally available CCR5 antagonist 6a as a clinical candidate. Full details of a structure–activity relationship (SAR) study and ADME properties are presented.
We also recommend Trading Suppliers and Manufacturers of 4-(4-Hydroxybutyl)benzoic acid Methyl ester (cas 123910-88-3). Pls Click Website Link as below: cas 123910-88-3 suppliers
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View